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Abstract
Background: Joint replacement is an effective intervention and prosthetic joint infection (PJI) is one of the most
serious complications of such surgery. Diagnosis of PJI is often complex and requires multiple modalities of
investigation. We describe a rare cause of PJI which highlights these challenges and the role of whole-genome
sequencing to achieve a rapid microbiological diagnosis to facilitate prompt and appropriate management.
Case presentation: A 79-year-old man developed chronic hip pain associated with a soft-tissue mass, fluid
collection and sinus adjacent to his eight-year-old hip prosthesis. His symptoms started after intravesical Bacillus
Calmette-Guerin (BCG) therapy for bladder cancer. Synovasure™ and 16S polymerase chain reaction (PCR) tests were
negative, but culture of the periarticular mass and genome sequencing diagnosed BCG infection. He underwent a
two-stage joint revision and a prolonged duration of antibiotic therapy which was curative.
Conclusions: BCG PJI after therapeutic exposure can have serious consequences, and awareness of this potential
complication, identified from patient history, is essential. In addition, requesting appropriate testing is required,
together with recognition that traditional diagnostics may be negative in non-pyogenic PJI. Advanced molecular
techniques have a role to enhance the timely management of these infections.
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Background
Joint replacement is a highly effective intervention and
with an aging population and advancements in joint
arthroplasty, demand is expected to increase [1]. Pros-
thetic joint infection (PJI) is one of the most serious
complications of joint replacement surgery and is associ-
ated with significant morbidity. PJI affects 1–2% of all
primary total hip and knee arthroplasties over the life-
time of the prosthetic joint and diagnosis and manage-
ment can be difficult, prolonged and costly [2].
Diagnosis often relies on the results of multiple investi-
gations including radiological, biochemical, microbio-
logical and molecular. In the following case we describe
a rare cause of PJI which highlights some of these diag-
nostic challenges.
Case presentation
A 79-year-old male presented to a tertiary orthopaedic
hospital in the United Kingdom with worsening pain
and difficulty weight bearing localised to his previously
asymptomatic total hip replacement. He had undergone
an uncomplicated metal on polyethylene total hip
replacement in 2008. Eighteen months prior to presenta-
tion to our unit he had developed a fluctuant swelling
over the right hip. The swelling intermittently dis-
charged serous fluid via a sinus which resolved spontan-
eously 2 months prior to presentation, after which he
reported persistent pain in the joint and significant
weight loss but no fevers or other systemic symptoms.
His past medical history included osteoarthritis of the
spine, ischaemic heart disease, two myocardial infarc-
tions, benign prostatic hyperplasia, pulmonary embolism
following a trans-urethral resection of the prostate and
transitional cell carcinoma of the bladder. For the latter
he received six intravesical BCG vaccine instillations
(Tice strain, Alliance Pharmaceuticals) over a 2 month
period. Within a month of receiving the final BCG instil-
lation the swelling over his right hip developed.
In view of the intermittently discharging sinus, the clin-
ical diagnosis at initial orthopaedic assessment was PJI.
Computed tomography of the pelvis showed a large col-
lection around the right hip extending into the adductor
compartment. The urinary tract appeared normal and
there was no evidence that the collection was associated
with any part of it. Magnetic resonance imaging (MRI) of
the hip demonstrated a large, lobulated soft tissue mass
arising in relation to the hip joint and prosthesis, which
was felt to be consistent with a diagnosis of metallosis and
pseudotumour due to aseptic lymphocyte-dominated
vasculitis-associated lesions (Fig. 1) [3].
The joint was aspirated and blood-stained fluid was
obtained which was negative on Gram staining and
standard microbiological testing (culture of fluid from a
normally sterile site including blood, chocolate,
fastidious anaerobic and Sabouraud agar; continuous
monitoring blood culture system and fastidious anaer-
obic enrichment broth) [4]. One month later the patient
underwent explantation of the joint, with insertion of a
vancomycin and meropenem impregnated articulating
cement spacer. Intraoperatively, extensive damage to the
ilium, ischium and pubis was noted, together with mul-
tiple turbid fluid collections in the adductor compart-
ment and around the medial aspect of the hip. Synovial
fluid alpha-defensin was negative (Synovasure™; an assay
for neutrophil antimicrobial peptides (NAMP) used to
support the diagnosis of PJI) [5]. Multiple intraoperative
bone and tissue samples underwent histological examin-
ation and microbiological culture, and post-operatively
the patient was treated empirically with meropenem and
vancomycin. Antimicrobial therapy was subsequently dis-
continued when standard microbiological cultures were
negative. While histology was not consistent with active
infection, samples did show a fibrinous exudate replacing
the synovial lining with abundant macrophages laden with
particulate debris (Fig. 2). No granulomas were identified
and no acid and alcohol fast bacilli were seen on Ziehl
Neelsen staining. Following discussion at the regional
bone infection multidisciplinary team meeting, residual
intra-operative samples underwent broad-range bacterial
16S ribosomal deoxyribonucleic acid (rDNA) PCR, which
was negative, and mycobacterial culture.
Five weeks post-operatively, tissue samples grew acid al-
cohol fast bacilli in liquid culture with a time to positivity
of 28–31 days (BD BACTEC™ MGIT™ Automated
Fig. 1 T1 MRI sequence of the pelvis showing the right total hip
replacement with a large lobulated associated soft tissue mass
arising in relation to the hip joint and the prosthesis (arrow),
consistent with prosthesis-related pseudotumour
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Mycobacterial Detection System, Becton Dickson, NJ,
USA). Within 5 days of the positive mycobacterial culture,
the bacilli were identified by whole-genome sequencing
(WGS) as Mycobacterium bovis (BCG lineage), and a
genotypic drug susceptibility profile was determined.
Although we had identified BCG from intra-operative
samples which was presumed to be a complication of pre-
vious intravesical therapy, we went on to further
investigate the origin of the BCG by comparing our
patient’s isolate with clinical BCG isolates from the Mid-
lands and North of England (ca 15M population) in the 2
years from January 2017 (a period during which sequen-
cing of M. tuberculosis complex isolates was operational).
A maximal likelihood phylogeny reconstructed using
iqTree 1.6.1 with a GTR model, outgroup rooted using a
lineage 1 isolate [6, 7]. We identified 28 isolates from 27
patients, which grouped into three, presumably corre-
sponding to the BCG preparations marketed by different
suppliers for vaccination or intravesical instillation (Fig. 3).
The isolate received by our patient, and eight other older
men who presumably also received intravesical BCG ther-
apy, differs from the BCG strains isolated from children in
the same time period (Fig. 3).
A six-month treatment regime with rifampicin, isonia-
zid, ethambutol and moxifloxacin was commenced
(pyrazinamide was excluded due to the intrinsic resistance
of M. bovis). The second stage revision was delayed until
completion of 12 weeks of this therapy, approximately 6
months after the first stage revision (explantation), with
an uncemented modular titanium femoral stem and
modular titanium revision shell with metal on polyethyl-
ene articulation. The patient is presently walking without
aid and without pain or clinical recurrence of PJI.
Discussion and conclusions
BCG is a live attenuated strain of M. bovis and has been
used as an intravesical immunotherapy for superficial
bladder cancer since 1976 [8]. Local complications of
intravesical BCG therapy are well recognised and include
cystitis and granulomatous prostatitis [9]. Systemic
complications due to disseminated BCG infection (e.g.
pneumonitis or granulomatous hepatitis) have also been
described. However, reports of M. bovis osteoarticular
infections following intravesical BCG instillation, and in
particular PJI, are extremely rare.
A review of the literature suggests that only eight such
cases have been reported to date, six of prosthetic hip
replacements and two in prosthetic knees [9]. The time
between intravesical instillation to the development of
symptomatic BCG PJI ranges from 7 days to years [9–16].
It has been suggested that early infection results from
haematogenous dissemination, which may be reduced by
delaying BCG therapy after surgical interventions and ur-
ethral catheterisation [17]. Several hypotheses have been
proposed to account for the delayed presentation of BCG
PJI. BCG is often found in the urine for > 12months after
therapy so probably breaches the bladder mucosa and is
transiently bloodborne, leading to seeding of the pros-
thesis [18, 19]. In our case the route of infection was likely
haematogenous as there was no evidence of malignant
spread from the bladder cancer or extension of the soft
tissue abnormalities to the bladder or renal tract.
One of the common features of other cases of BCG
PJI is the prolonged time between patient presentation
and final diagnosis. Possible reasons include lack of clin-
ical suspicion and appropriate diagnostic testing for
mycobacteria, different patterns of inflammation relative
to other bacteria, as well as the extended culture time
required due to slow mycobacterial replication rate.
Such delay may have significant implications for the ini-
tiation of appropriate treatment. In addition, the speci-
ation of bacilli in mycobacterial cultures and traditional
phenotypic drug sensitivity testing may increase labora-
tory turnaround times by several weeks.
In this case, diagnostic delay was due to low clinical
suspicion and therefore mycobacterial cultures were not
initially attempted. Once material was cultured in liquid
cultures, and analysed by WGS, a microbiological diag-
nosis was rapidly achieved and appropriate surgical and
medical management instituted, including targeted anti-
Fig. 2 a The synovial lining is replaced by a fibrinous exudate (H&E, × 100). b Infiltrate of histiocytes with particulate material in their cytoplasm
(H&E, × 400)
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mycobacterial chemotherapy based on genotypic drug
susceptibility testing (DST) data [20]. However, WGS
still relies on bacterial culture and while it offers advan-
tages over other molecular methods of speciation, it re-
mains relatively costly and requires complex analytical
pipelines [21]. A recent advancement on the targeted
amplicon sequencing used in pan-bacterial 16S rDNA
PCR is shotgun metagenomic next-generation sequen-
cing which has the potential to broaden the unbiased de-
tection of pathogens directly from clinical samples in
culture-negative PJI [22–24]. However, it is still predom-
inantly a research technique and its widespread adoption
in routine clinical diagnostics is currently limited by low
yields of pathogenic DNA recovered from samples, high
costs and complex data processing [25].
It should be noted that while the inclusion of synovial
alpha-defensin testing, such as Synovasure™, in the diag-
nostic pathway for PJI is being increasingly advocated,
our case demonstrates that negative NAMP assays occur
in non-pyogenic infections, potentially resulting in the
exclusion of PJI with implications for subsequent surgi-
cal decision-making (e.g. whether to proceed to a one or
two stage revision) [5].
As this case illustrates, BCG infection after therapeutic
exposure can have serious consequences, and monitor-
ing the frequency of this complication is important.
Three distinct groups of BCG isolates were identified,
presumably corresponding to the products of different
suppliers; WGS-based approaches to identifying the
likely source may contribute to this goal, as well as
unambiguously differentiating BCG from more virulent
M. bovis isolates.
In summary, we describe the use of mycobacterial
WGS for the rapid identification of M. bovis PJI occur-
ring after intravesical BCG therapy. The benefits of this
approach included a rapid diagnosis, definitive exclusion
of infections with other M. tuberculosis complex mem-
bers, and the timely initiation of appropriate antimicro-
bial therapy. Ongoing advances in sample processing,
including culture-independent techniques, have the po-
tential to reduce turnaround times further. This case
also highlights the application of WGS for detecting and
monitoring rare but serious complications following
BCG exposure (which should be considered in PJI cases),
contributing to detection and surveillance of such
serious complications.
Fig. 3 A maximal likelihood phylogeny reconstructed of 28 BCG isolates from 27 patients, isolated from clinical samples from the Midlands and
North of England 2017 and 2018. A BCG Pasteur isolate is included. Identical sequences are collapsed into a single node, marked with the
demographics of the cases comprising it. Our case is one of the nine adults at the top of the tree. Three distinct groups of cases are seen –
children under two (right, bottom), older adults (top) and a smaller, mixed group (left)
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